Zymeworks Inc. (NASDAQ:ZYME) finished Wednesday with an addition of $0.11 to close at $7.97, an upside of 1.40 percent. An average of 561,400 shares of common stock have been traded in the last five days. There was a gain of $0.70 in the past week, and it reached a new high 14 times over the past 12 months. The last 20 days have seen an average of 617,000 shares traded, while the 50-day average volume stands at 748,800.
ZYME stock has increased by 6.98% in the last month. The company shares reached their 1-month lowest point of $6.61 on 08/11/23. With the stock rallying to its 52-week high on 01/19/23, shares of the company touched a low of $4.11 and a high of $10.80 in 52 weeks. It has reached a new high 7 times so far this year and achieved 1.40% or $0.11 in price. In spite of this, the price is down -26.20% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
ZYME stock investors should be aware that Zymeworks Inc. (ZYME) stock had its last reported insider trading activity 167 days ago on Jun 16. In this transaction, the insider spent $23,298. SVP & Chief Financial Officer, Astle Christopher, disposed of 887 shares at a price of $6.01 on Dec 12. The insider now owns more than $5,331 worth of shares. Prior to that, Chief Medical Officer Josephson Neil went on to Sale 2,475 shares at $8.10 each on Nov 10. An amount of $20,045 was transacted.
Valuation Metrics
Zymeworks Inc. (ZYME) has a trailing price-to-earnings (P/E) ratio of 2.86. The stock’s beta is 0.90. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.20, the price-to-book (PB) ratio at 1.19, and the price-to-cash flow ratio at 3.37.
Financial Health
The quick ratio of Zymeworks Inc. for the three months ended June 29 was 4.50, and the current ratio was 4.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Zymeworks Inc.’s EBITDA margin for the year ending June 29 is 36.72%, while its operating margin for the same period stands at 41.90%. Its gross profit as reported stood at $203.89 million compared to revenue of $412.48 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Zymeworks Inc.’s return on assets was 34.60%.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$51.15 million in the quarter, while revenues of -$24.35 million were shrunk -26.33%. The analyst consensus anticipated Zymeworks Inc.’s latest quarter earnings to come in at -$0.47 per share, but it turned out to be -$0.76, a -61.70% surprise. For the quarter, EBITDA amounted to -$49.6 million. Shareholders own equity worth $67.83 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Zymeworks Inc. (ZYME) price momentum. RSI 9-day as of the close on 23 August was 64.98%, suggesting the stock is Neutral, with historical volatility in this time frame at 54.56%.
As of today, ZYME’s price is $7.65 +9.63% or $0.70 from its 5-day moving average. ZYME is currently trading +6.13% higher than its 20-day SMA and -9.02% lower than its 100-day SMA. However, the stock’s current price level is -4.67% below the SMA50 and +8.29% above the SMA200.
The stochastic %K and %D were 87.21% and 76.59%, respectively, and the average true range (ATR) was 0.33. With the 14-day stochastic at 89.47% and the average true range at 0.34, the RSI (14) stands at 57.85%. The stock has reached 0.32 on the 9-day MACD Oscillator while the 14-day reading was at 0.33.
Analyst Ratings
The consensus rating for Zymeworks Inc. (ZYME) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ZYME, while 3 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 8 others rate it as a “buy”.
What is ZYME’s price target for the next 12 months?
Analysts predict a range of price targets between $8.00 and $19.00, with a median target of $13.00. Taking a look at these predictions, the average price target given by analysts for Zymeworks Inc. (ZYME) stock is $13.52.
